NASDAQ:ATRA Atara Biotherapeutics (ATRA) Stock Price, News & Analysis $9.75 +0.35 (+3.72%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Atara Biotherapeutics Stock (NASDAQ:ATRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Atara Biotherapeutics alerts:Sign Up Key Stats Today's Range$9.05▼$9.7950-Day Range$7.81▼$10.2352-Week Range$3.92▼$19.15Volume47,598 shsAverage Volume626,449 shsMarket Capitalization$97.89 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingModerate Buy Company Overview Atara Biotherapeutics, Inc. is a biotechnology company focused on developing T-cell immunotherapies for cancer and serious diseases associated with viral infections. The company’s approach uses allogeneic, or donor-derived, T cells that are selected or engineered to recognize disease-related targets, with the goal of providing off-the-shelf treatment options. Atara’s lead product, Ebvallo (tabelecleucel), is an allogeneic T-cell immunotherapy designed to treat Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) in certain patients who have received a solid-organ or hematopoietic-cell transplant. Ebvallo received marketing authorization in the European Union and is commercialized in international markets through collaboration arrangements. The company has also developed investigational programs in areas including multiple sclerosis and oncology, although its pipeline has changed over time as programs have advanced or been discontinued. Founded in 2012 and headquartered in Thousand Oaks, California, Atara has focused primarily on serving patients in the United States and international markets through regulatory submissions, partnerships and commercialization agreements. Pascal Touchon has served as the company’s president and chief executive officer. As with other biotechnology companies, Atara’s product portfolio and corporate structure may change as clinical, regulatory and commercial activities progress.AI Generated. May Contain Errors. Read More Atara Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreATRA MarketRank™: Atara Biotherapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 741st out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingModerate Buy Consensus RatingAtara Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Atara Biotherapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAtara Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Atara Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atara Biotherapeutics are expected to grow in the coming year, from ($0.22) to $1.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atara Biotherapeutics is -8.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atara Biotherapeutics is -8.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Atara Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.85% of the float of Atara Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverAtara Biotherapeutics has a short interest ratio ("days to cover") of 7.34.Change versus previous monthShort interest in Atara Biotherapeutics has recently decreased by 5.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Atara Biotherapeutics this week, compared to 5 articles on an average week. Company Ownership4.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $959,093.00 in company stock, which represents 0.9869% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have bought 2,344.91% more of their company's stock than they have sold. Specifically, they have bought $999,994.00 in company stock and sold $40,901.00 in company stock.Percentage Held by Insiders41.20% of the stock of Atara Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atara Biotherapeutics' insider trading history. Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATRA Stock News HeadlinesAtara Resubmits Tabelecleucel BLA To FDASeptember 30, 2026 | rttnews.comAtara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug AdministrationSeptember 30, 2026 | businesswire.comElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt without major changes. As former head of the Department of Government Efficiency under President Trump, Musk saw firsthand how looming spending cuts could rattle markets and squeeze 401ks, IRAs, and TSPs. A preserved IRS provision may help everyday investors shield their retirement savings before the next wave of volatility hits.October 6 at 1:00 AM | American Hartford Gold (Ad)Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational ProgressAugust 12, 2026 | finance.yahoo.comAtara Biotherapeutics Announces $15 Million Registered Direct OfferingJuly 7, 2026 | businesswire.comQuetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic LeukemiaJune 11, 2026 | globenewswire.comAtara Biotherapeutics Inc (ATRA)May 31, 2026 | investing.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRAMay 26, 2026 | prnewswire.comSee More Headlines ATRA Stock Analysis - Frequently Asked Questions How have ATRA shares performed this year? Atara Biotherapeutics' stock was trading at $18.09 at the beginning of the year. Since then, ATRA stock has decreased by 46.5% and is now trading at $9.68. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its quarterly earnings data on Wednesday, August, 12th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.01. The biotechnology company had revenue of $0.63 million for the quarter, compared to analyst estimates of $0.55 million. When did Atara Biotherapeutics' stock split? Atara Biotherapeutics shares reverse split on the morning of Thursday, June 20th 2024.The 1-25 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Atara Biotherapeutics IPO? Atara Biotherapeutics (ATRA) raised $75 million in an initial public offering (IPO) on Thursday, October 16th 2014. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Atara Biotherapeutics? Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atara Biotherapeutics investors own include Agenus (AGEN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Athersys (ATHX), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY) and FuelCell Energy (FCEL). Company Calendar Last Earnings8/12/2026Today10/06/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 4 days ago, ATRA's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ATRA CIK1604464 Webwww.atarabio.com Phone(805) 623-4211FaxN/AEmployees10Year Founded2012Price Target and Rating Average Price Target for Atara Biotherapeutics$9.50 High Price Target$13.00 Low Price Target$6.00 Potential Upside/Downside+2.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$32.69 million Net Margins-269.42% Pretax Margin-268.95% Return on EquityN/A Return on Assets-73.01% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio1.98 Sales & Book Value Annual Sales$120.77 million Price / Sales0.77 Cash Flow$4.75 per share Price / Cash Flow1.95 Book Value($5.34) per share Price / Book-1.74Miscellaneous Outstanding Shares10,040,000Free Float5,902,000Market Cap$93.07 million OptionableNo Data Beta0.21 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ATRA) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises...Priority Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredWhy The Biggest Names in AI Are Heading To The ArcticGoogle contracted over 12 GW of energy last year and just announced a 15 billion dollar AI infrastructure inve...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
